The FLT3 gene mutation was the major biomarker of response to CA4948, S63845, and PU-H71 treatment, with elevated susceptibility of AML cells with the FLT3 gene mutation at an allelic ratio of >0.5. Here, FLT3 is linked to acute myeloid leukemia.